Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEKFree Report) in a research note published on Wednesday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Trading Up 3.4 %

Shares of Check-Cap stock opened at $2.30 on Wednesday. The business’s 50 day simple moving average is $2.26 and its 200-day simple moving average is $2.53. The stock has a market capitalization of $13.46 million, a price-to-earnings ratio of -0.76 and a beta of 0.28. Check-Cap has a twelve month low of $1.27 and a twelve month high of $4.63.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Featured Stories

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.